MiMedx Group, Inc. — Q1 2023 Form 10-Q Summary
Business Context and Reporting Period
MiMedx develops and sells placental biologics primarily for acute and chronic non-healing wounds and is advancing a late-stage biologics pipeline for knee osteoarthritis. Its reportable segments are Wound & Surgical and Regenerative Medicine. The filing covers the three months ended March 31, 2023, compared with the same period in 2022.
Financial Performance and Position
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $71.7 million | $58.9 million | +21.7% |
| Gross profit | $59.3 million | $49.0 million | +21.0% |
| Gross margin | 82.7% | 83.1% | Down 40 bps |
| Operating loss | $(3.4) million | $(9.3) million | Improved $5.9 million |
| Net loss | $(5.0) million | $(10.5) million | Improved $5.5 million |
| Net loss available to common stockholders | $(6.7) million | $(12.1) million | Improved $5.4 million |
| Basic and diluted loss per share | $(0.06) | $(0.11) | Improved |
| EBITDA | $(2.5) million | $(8.3) million | Improved |
| Adjusted EBITDA | $5.5 million | $(1.7) million | Improved $7.3 million |
| Adjusted EBITDA margin | 7.7% | (2.9)% | Improved |
| Cash flow from operations | $(4.0) million | $(10.2) million | Improved $6.2 million |
Sales growth was led by Advanced Wound Care Tissue/Other products, which increased to $65.8 million from $52.9 million. Cord product sales were $5.4 million versus $5.6 million. Wound & Surgical sales increased 21.1% to $70.6 million, while Regenerative Medicine generated no revenue and incurred $5.0 million of research and development expense.
Cash and cash equivalents were $61.2 million at March 31, 2023, down from $66.0 million at December 31, 2022. Current assets were $131.7 million and current liabilities were $40.9 million, producing a reported current ratio of 3.2. Inventory increased to $14.7 million from $13.2 million, and accounts receivable increased to $44.7 million from $43.1 million.
The Company had $50.0 million of principal outstanding under its senior secured term loan, reported at $48.7 million net of financing costs and discount. The loan matures June 30, 2025, bears interest at 11.9% as of March 31, 2023, and requires no principal payments before maturity. The Company reported compliance with its financial covenants.
Series B Convertible Preferred Stock had a carrying value of $92.5 million. Accumulated but undeclared and unpaid dividends were $15.5 million, and the preferred stock was convertible into approximately 30.0 million common shares as of March 31, 2023.
Material Changes Versus the Prior Comparable Period
- Revenue increased $12.8 million, primarily from new products launched in the third quarter of 2022, stronger private-office sales, reduced COVID-related disruption, and one additional shipping day.
- Gross margin declined modestly because cost of sales grew faster than revenue.
- SG&A increased 5.5% to $52.3 million due mainly to higher commissions and travel, partially offset by lower personnel and professional-services costs.
- Research and development expense increased 8.9% to $6.5 million as the registrational knee osteoarthritis clinical trial commenced.
- Investigation, restatement and related expense rose 43.9% to $3.7 million, partly because the prior-year period included a recovery of expenses previously advanced for a former officer.
- Interest expense increased 37.9% to $1.6 million because of higher reference interest rates on the term loan.
- Operating cash use improved to $4.0 million from $10.2 million, although the Company remained cash-flow negative from operations.
- The Company issued significant equity awards, including a CEO performance grant covering 3.3 million performance stock units and a 3.6 million-share performance option. Share-based compensation expense was $4.3 million in Q1 2023.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing cash and cash generated from operations are expected to be sufficient to meet obligations as they come due for the 12 months following the filing date. Anticipated cash requirements include product investments, regulatory and international expansion activities, clinical trials, research and development, legal and consulting costs, and severance payments.
The Company is pursuing FDA-related regulatory pathways for its biologics pipeline and international expansion, including initial EPIFIX sales in Japan. Regenerative Medicine currently produces no revenue and depends on continued clinical and regulatory progress.
Material risks include continued operating losses and negative operating cash flow; the $50.0 million term loan maturity in 2025 and exposure to variable interest rates; covenant compliance and potential debt acceleration; regulatory approval and reimbursement uncertainty; dependence on tissue supply and manufacturing compliance; ongoing litigation and indemnification obligations; and the effects of the prior Audit Committee Investigation and related restatement matters.
The Company has potential obligations under the Nordic Agreement of up to $10.2 million tied to clinical milestones, of which $3.6 million had been paid through March 31, 2023. It also has a potential $9.6 million milestone payment under the Turn Agreement if FleX receives FDA 510(k) clearance; clearance had not been received, and management did not anticipate payment in 2023.
The Company agreed to pay its former CEO $3.1 million through September 2024; $0.9 million was paid in Q1 2023. It also paid $0.2 million toward legal matters during the quarter and had not accrued for potential losses related to legal matters as of March 31, 2023.
Investor Verification Checklist
- Verify whether revenue growth and the 7.7% adjusted EBITDA margin are sustainable after COVID-related comparisons, new-product benefits, and the additional selling day.
- Monitor operating cash flow, working-capital movements, and whether cash remains sufficient through the June 2025 term-loan maturity.
- Review the term-loan covenants, variable-rate exposure, refinancing requirements, and potential mandatory prepayments.
- Assess the dilution and economic implications of the Series B Preferred Stock, accumulated dividends, and outstanding equity awards.
- Track progress, costs, and regulatory outcomes for the knee osteoarthritis clinical program and other biologic candidates.
- Review pending litigation, former-officer indemnification obligations, investigation-related expenses, and unaccrued potential losses.
- Confirm the timing and probability of Nordic clinical milestones and the contingent Turn Agreement payment.